This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 Jun 5;370(23):2238-9.

doi: 10.1056/NEJMe1405078.

Pharmacology and the treatment of complicated skin and skin-structure infections

Henry F Chambers¹

Affiliations

Affiliation

¹ From the Department of Medicine, University of California, San Francisco, and the Division of Infectious Diseases, San Francisco General Hospital - both in San Francisco.

PMID: 24897088
DOI: 10.1056/NEJMe1405078

Editorial

Pharmacology and the treatment of complicated skin and skin-structure infections

Henry F Chambers. N Engl J Med. 2014.

. 2014 Jun 5;370(23):2238-9.

doi: 10.1056/NEJMe1405078.

Author

Henry F Chambers¹

Affiliation

¹ From the Department of Medicine, University of California, San Francisco, and the Division of Infectious Diseases, San Francisco General Hospital - both in San Francisco.

PMID: 24897088
DOI: 10.1056/NEJMe1405078

No abstract available

PubMed Disclaimer

Comment on

Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Boucher HW, et al. N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480. N Engl J Med. 2014. PMID: 24897082 Clinical Trial.
Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators. Corey GR, et al. N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422. N Engl J Med. 2014. PMID: 24897083 Clinical Trial.

Similar articles

Dalbavancin or oritavancin for skin infections.
Corey GR, Jiang H, Moeck G. Corey GR, et al. N Engl J Med. 2014 Sep 18;371(12):1162-3. doi: 10.1056/NEJMc1407925. N Engl J Med. 2014. PMID: 25243251 No abstract available.
Dalbavancin or oritavancin for skin infections.
Baang J, Fisher S. Baang J, et al. N Engl J Med. 2014 Sep 18;371(12):1160-1. doi: 10.1056/NEJMc1407925. N Engl J Med. 2014. PMID: 25229924 No abstract available.
Dalbavancin or oritavancin for skin infections.
Núñez-Núñez M, Rodríguez-Baño J. Núñez-Núñez M, et al. N Engl J Med. 2014 Sep 18;371(12):1160. doi: 10.1056/NEJMc1407925. N Engl J Med. 2014. PMID: 25229923 No abstract available.
Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD, Sulaiman RM, Rybak MJ. Roberts KD, et al. Pharmacotherapy. 2015 Oct;35(10):935-48. doi: 10.1002/phar.1641. Pharmacotherapy. 2015. PMID: 26497480 Review.
Two new drugs for skin and skin structure infections.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5. Med Lett Drugs Ther. 2014. PMID: 25118799 Review. No abstract available.

See all similar articles

Cited by

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis.
Rose WE, Hutson PR. Rose WE, et al. Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):36-40. doi: 10.1007/s40801-020-00188-6. Drugs Real World Outcomes. 2020. PMID: 32588386 Free PMC article.
Evaluation of Physician Prescribing Patterns For Antibiotics in the Treatment of Nonnecrotizing Skin and Soft Tissue Infections.
Ezebuenyi MC, Brakta F, Onor IO, Sarpong DF, Bryant-Burks K, Figueroa JE 2nd. Ezebuenyi MC, et al. P T. 2018 May;43(5):287-292. P T. 2018. PMID: 29719370 Free PMC article.
New agents approved for treatment of acute staphylococcal skin infections.
Tatarkiewicz J, Staniszewska A, Bujalska-Zadrożny M. Tatarkiewicz J, et al. Arch Med Sci. 2016 Dec 1;12(6):1327-1336. doi: 10.5114/aoms.2016.59838. Epub 2016 May 11. Arch Med Sci. 2016. PMID: 27904526 Free PMC article.
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG. Bulik CC, et al. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27872075 Free PMC article.
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, Ralph Corey G. Deck DH, et al. Infect Dis Ther. 2016 Sep;5(3):353-61. doi: 10.1007/s40121-016-0119-9. Epub 2016 Jul 1. Infect Dis Ther. 2016. PMID: 27370913 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information